Hims & Hers Health (NYSE:HIMS) Stock Price Target Cut by Jefferies Financial Group

Posted by Grant Hamersma on Nov 10th, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price target decreased by equities research analysts at Jefferies Financial Group from $31.00 to $24.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Jefferies Financial Group‘s price target indicates a potential upside of 26.12% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Truist Financial boosted their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research report on Monday, August 24th. TD Cowen lifted their price target on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. initiated coverage on Hims & Hers Health in a report on Friday, September 11th. They issued a “neutral” rating and a $32.00 price objective for the company. Bank of America upped their price objective on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Finally, Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average price target of $31.53.

Get Our Latest Research Report on HIMS

Hims & Hers Health Stock Down 17.0%

Shares of Hims & Hers Health stock traded down $3.91 on Tuesday, hitting $19.03. 57,894,076 shares of the company’s stock traded hands, compared to its average volume of 22,403,338. The stock has a market cap of $4.44 billion, a P/E ratio of -30.21 and a beta of 2.53. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The firm’s 50-day moving average is $28.31 and its 200 day moving average is $26.91. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $41.28.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The company had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter last year, the firm posted $0.17 EPS. The firm’s quarterly revenue was up 38.2% on a year-over-year basis. Equities analysts anticipate that Hims & Hers Health will post -0.16 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 2,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $29.70, for a total value of $59,400.00. Following the transaction, the chief financial officer owned 234,527 shares of the company’s stock, valued at $6,965,451.90. This trade represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 3,462 shares of the company’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total value of $95,551.20. Following the transaction, the insider directly owned 293,886 shares of the company’s stock, valued at $8,111,253.60. This trade represents a 1.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 133,905 shares of company stock valued at $3,826,977 in the last quarter. Insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Bank of America Corp DE increased its stake in shares of Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after purchasing an additional 2,877,550 shares during the period. State of Michigan Retirement System grew its holdings in Hims & Hers Health by 13.7% in the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock worth $48,549,000 after buying an additional 280,900 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Hims & Hers Health in the 2nd quarter valued at approximately $46,220,000. Bienville Capital Management LLC acquired a new stake in Hims & Hers Health in the 2nd quarter valued at approximately $27,242,000. Finally, Principal Financial Group Inc. increased its position in Hims & Hers Health by 97.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock valued at $26,620,000 after acquiring an additional 632,282 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Q3 revenue rose 49% year over year to $890.4 million, showing continued business growth, although it came in just below analysts’ expectations. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors
Neutral Sentiment: The company plans to offer an unapproved peptide after U.S. restrictions eased. The move could create a growth opportunity, but its commercial and regulatory impact is uncertain. Article: Hims & Hers to offer an unapproved peptide after US eases curbs
Negative Sentiment: Q3 earnings per share were $0.03, below estimates of $0.06–$0.07. Gross margin also contracted sharply, while subscribers fell by 100,000 sequentially to 2.8 million—raising questions about growth quality and costs. Article: Hims & Hers: Why I’m Not Buying Back Yet
Negative Sentiment: Management lowered its 2026 adjusted EBITDA outlook to $257 million–$277 million, from $300 million–$375 million previously. Its Q4 revenue forecast of $875 million–$895 million is also well below the roughly $956 million analyst consensus; the full-year revenue range is $3.1 billion–$3.2 billion. Article: Hims & Hers narrows 2026 revenue forecast as margins contract
Negative Sentiment: Analysts cut price targets: Morgan Stanley lowered its target to $25 and Needham to $32, though Needham maintained a Buy rating. Article: Hims & Hers Stock Feels a Pinch Tuesday

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.